First National Trust CO Annovis Bio, Inc. Put Options Transaction History
First National Trust CO
- $2.44 Billion
- Q1 2025
Put Options
0 transactions
| Quarter | Operation | Price Per put | puts change | puts Held | SEC Form |
|---|
Others Institutions Holding ANVS
# of Institutions
50Shares Held
1.99MCall Options Held
348KPut Options Held
535K-
Vanguard Group Inc Valley Forge, PA648KShares$958,9210.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il215KShares$318,5060.0% of portfolio
-
Ubs Group Ag161KShares$238,0960.0% of portfolio
-
Geode Capital Management, LLC Boston, MA153KShares$225,8670.0% of portfolio
-
Susquehanna International Group, LLP Bala Cynwyd, PA128KShares$189,0030.0% of portfolio
About Annovis Bio, Inc.
- Ticker ANVS
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 8,163,920
- Market Cap $12.1M
- Description
- Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease ...